Vasculitis and Giant Cell Arteritis News

Patients with giant cell arteritis who use anticoagulants demonstrate lower risks for vision loss, stroke and other cranial ischemic complications, according to data published in Annals of the Rheumatic Diseases.

SAN DIEGO — Imaging techniques are poised to streamline the diagnosis of giant cell arteritis in the United States, after gaining traction elsewhere, according to a speaker at the 2024 Congress of Clinical Rheumatology West.

SAN DIEGO — Diagnosing giant cell arteritis and polymyalgia rheumatica can “fascinate” and cause “trepidation” in equal measure due to their similarities and complications, said a speaker at the 2024 Congress of Clinical Rheumatology West.

Tapering tocilizumab leads to a longer relapse-free period in patients with giant cell arteritis, compared with abrupt discontinuation, according to data published in Seminars in Arthritis and Rheumatism.

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended the launch of proposed biosimilar rituximab candidate Ituxredi, Dr. Reddy’s Laboratories announced in a press release.

An growing therapeutic armamentarium for antineutrophil cytoplasmic antibody-associated vasculitis — including avacopan and azathioprine — is providing rheumatologists with an increasingly robust array of options, according to a presenter.

Glucocorticoids are an effective go-to treatment for giant cell arteritis, but discontinuing them can be difficult, according to a presenter at the 2024 AWIR annual conference.

Nearly all rheumatologists who responded to a recent survey reported patients with giant cell arteritis are in dire need of new treatments, according to a market analysis from Spherix Global Insights.

It has been at least 2 years since the first cohort of patients with lupus underwent chimeric antigen receptor T-cell treatment, and, at least so far, for every one of them, each new dawn represents another day spent in full remission.